maintain market perform rate share
increas price target follow review
oper result result better expect
believ share fairly-valu given rel low product
sale growth balanc legaci product headwind new
product opportun growth
report oper result yesterday
market close provid updat key initi overal
result ahead expect non ep vs
revenu vs consensu base
result increas non-gaap ep guidanc
revenu guidanc
financi perform driven product sale growth
new product sale growth slightli offset declin legaci
product year-over-year increas repatha sale
prolia sale xgeva sale kyproli sale
year-over-year declin enbrel sale epogen
sale aranesp sale sale
term potenti headwind increas rebat
repatha competit categori highlight
expect launch first neulasta biosimilar longer term
plan potenti chang reimburs us
target volum driven product growth plan price
increas juli cancel
particular focu recent approv launch cgrp
antibodi aimovig erenumab migrain prevent
highlight coverag cover live patient hub
handl larg bolu patient request alloc major
patient free drug program coverag isnt
place extend patient support payer negoti
term patient access current coverag suggest
physician attest failur prior treatment
term pipelin program progress
develop highlight resubmiss even fda
osteoporosi follow adjud cardiac event
antibodi migrain prevent proof-of-concept data
bite portfolio clinic candid focu bcma
bite data myeloma biosimilar herceptin
humira would note growth herceptin sub potenti
biosimilar barrier us view biosimilar
strategi appropri risk-mitig step biosimilar
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani prioriti stock list
compani data secur llc estim reuter
review financi perform
close yesterday report result provid regulatori product updat
report non-gaap ep versu consensu compar non-gaap ep
year-ago period revenu billion vs estim billion consensu
billion sequenti year-over-year basi
expens side non-gaap cog repres non-gaap
revenu non-gaap sg expens revenu
due product launch market expens effect tax rate
quarter came versu basi point decreas due impact
 tax reform partli off-set prior year benefit settlement certain tax issu
compani cash posit stood billion quarter-end vs billion year-end total debt
stand billion compani share base stand million dilut share
share count quarter-end million million year-ago quarter
base million year-end repurchas million share cost billion
quarter compani dividend announc previous term
cash flow gener billion free cash flow vs billion year-ago
provid updat guidanc total revenu guidanc decreas rang
prior rang adjust non-gaap ep guidanc decreas
rang compar prior rang non-gaap tax rate remain
unchang capit expenditur also remain unchang
total product sale yoy sequenti driven double-digit
volume-driven growth new recent launch product includ repatha parsabiv
prolia sale vs consensu yoy sequenti driven
primarili unit volum lesser extent net sell price
kyproli sale vs consensu yoy sequenti
driven higher unit demand off-set partial net sell price
repatha sale vs consensu yoy sequenti
driven primarili higher unit demand off-set net sell price note repatha rebat may
increas
xgeva sale vs consensu yoy sequenti driven
higher unit demand lesser extent net sell price
neulasta sale vs consensu yoy sequenti
declin driven lower unit demand acknowled potenti biosimilar competit
sequenti changeyear/year except per share compani report factset secur llc estimatesconsensusamgn first inc
highlight advantag onpro devic provid patient benefit also
improv effici oper healthcar provid
sale vs consensu yoy
sequenti driven biosimilar competit accord taken major
enbrel sale vs consensu yoy sequenti
yoy declin driven primarili volum declin chang inventori benefit
increas inventori
aranesp sale vs consensu yoy sequenti
yoy declin driven mainli impact competit unit demand lesser extent
epogen sale vs consensu yoy sequenti
yoy declin driven primarili lower net sell price due extend suppli agreement
lesser extent lower unit demand
sensipar sale vs consensu yoy
sequenti yoy declin driven mainli unfavor inventori chang lower unit demand
result parsabiv uptak
sale parsabiv launch
neurosci follow recent launch aimovig file sbla autoinjector
pre-filled syring europ chmp recommend approv expect product launch
expect phase data antibodi migrain prevent
key question whether inhibit rescu patient sub-optimal respons aimovig
alzheim diseas ad program highlight nvs-partner beta amyloid convert
enzym bace inhibitor current phase test alzheim prevent amgn
decod genet subsidiari establish genet epidemiolog data determin rate
cognit declin patient risk allel interact age note
subject present ad risk allel believ beta-
amyloid accumul decad time patient symptomat damag may
repair given posit nv elect evalu nvss oral bace inhibitor
amg/cnp cognit normal patient age year risk factor
nv initi two phase trial gener data expect
nv lead placebo-control trial cognit unimpair
subject homozyg risk allel risk onset clinic symptom
patient random placebo primari endpoint time diagnosi mild
cognit impair dementia associ ad chang alzheim prevent
initi composit cognit apcc test score year apcc composit
repeat batteri assess neurolog statu rban mini-ment state
nv lead placebo-control trial cognit
unimpair subject least risk allel heterozyg elev brain amyloid
evidenc pet primari endpoint time diagnosi mild cognit impair
dementia associ ad chang alzheim prevent initi composit
cognit apcc test score year apcc composit repeat batteri
assess neurolog statu rban mini-ment state examin mmse raven
oncolog highlight kyproli imlyg blincyto
kyproli overal surviv ad eu label complet
enrol candor phase trial compar kyprolis/dexamethason /- darzalex
patient fail prior therapi primari endpoint progress free
surviv data expect
imlyg merck complet enrol trial compar
keytruda combin keytruda imlyg melanoma subject
checkpoint inhibitor therapi nave advanc set adjuv use exclus
criterion system therapi nave wild type diseas prior braf/mek inhibitor
therapi allow mutat posit patient primari endpoint data
blincyto receiv full approv eu adult patient philadelphia
neg relapsed/refractori acut lymphocyt leukemia base overal surviv data
tower trial
earli stage phase pipelin advanc addit bispecif cell engag
bite clinic long act version blincyto hematolog
malign long act bite target acut myeloid leukemia
aml bispecif antibodi refractori myeloma
target car-t small cell lung cancer expect phase data short-
act bcma bite myeloma short act bite aml
note compani depriorit bcma antibodi drug conjug
follow review initi data view data support view bite may
superior current adc
updat note includ new repatha indic europ adult establish
atherosclerot cardiovascular risk base fourier outcom trial bone franchis
note approv prolia glucocorticoid-induc osteoporosi follow receipt complet
respons letter fda refil bla even treatment
osteoporosi postmenopaus women high risk fractur complet comprehens
review clinic databas re-adjud cardiovascular event previous
identifi imbal alendron trial remain independ expert conclud
like due chanc
biosimilar launch kanjinti biosimilar herceptin europ
receiv biosimilar remicad complet primari analysi phase trial
rheumatoid arthriti
price target
arriv price target appli multipl ep estim
risk includ greater expect eros base biolog busi competit kyproli
gener velcad emerg myeloma treatment failur gain approv proprietari
expens price-to-earnings basi rel growth view face signific headwind
biosimilar brand competit legaci franchis
larg cap global commercial-stag biotechnolog compani discov develop biolog
small molecul drug specialti physician discoveri pipelin led compani
broaden focu oncolog immune-medi inflammatori diseas renal diseas includ
bone diseas cardiovascular neurolog diseas addit taken lead posit
develop biosimilar compani face near-term biosimilar competit legaci
